4 April 2016 ORYZON Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer’s Disease
16 February 2016 Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum
29 January 2016 Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease
29 December 2015 Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors